28317028|t|Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease
28317028|a|The mycobacterial caseinolytic protease ClpP1P2 is a degradative protease that recently gained interest as a genetically and pharmacologically validated drug target for tuberculosis. The first whole-cell active ClpP1P2 inhibitor, the human proteasome inhibitor bortezomib, is currently undergoing lead optimization to introduce selectivity for the bacterial target. How inhibition of ClpP1P2 translates into whole-cell antimicrobial activity is little understood. Previous work has shown that the caseinolytic protease gene regulator ClgR is an activator of the clpP1P2 genes and also suggested that this transcription factor may be a substrate of the protease. Here, we employ promoter activity reporters and direct mRNA level measurements showing that bortezomib treatment of Mycobacterium bovis BCG increased transcription of clpP1P2 and other ClgR - dependent promoters, suggesting that inhibition of ClpP1P2 increases cellular ClgR levels. Then, we carried out red fluorescent protein - ClgR fusion analyses to show that ClgR is indeed a substrate of ClpP1P2 and to identify ClgR's C-terminal nonapeptide APVVSLAVA as the signal sufficient for recognition and efficient protein degradation by ClpP1P2. Interestingly, accumulation of ClgR appears to be toxic for bacilli, suggesting a mechanism for how pharmacological inhibition of ClpP1P2 protease activity by bortezomib translates into whole-cell antibacterial activity. IMPORTANCE With 9 million new cases and more than 1 million deaths per year, tuberculosis, caused by Mycobacterium tuberculosis, is the biggest infectious disease killer globally. New drugs for the treatment of the drug-resistant forms of the disease are needed. Recently, a new target -lead couple, the mycobacterial protease ClpP1P2 and the human anticancer drug bortezomib, was identified. However, we know little about how expression of this protease is regulated, which proteins in the bacterium it degrades, how the protease recognizes its target proteins, and how the inhibition of ClpP1P2 exerts whole-cell antimicrobial activity. Here, we show that the ClpP1P2 protease regulates its own expression, and we identified a new substrate and a new substrate recognition sequence and a mechanism for how ClpP1P2 inhibition causes bacterial growth inhibition.
28317028	0	13	Mycobacterial	T007	UMLS:C0026912
28317028	14	50	Caseinolytic Protease Gene Regulator	T103	UMLS:C1336776
28317028	51	55	ClgR	T103	UMLS:C1336776
28317028	74	95	Caseinolytic Protease	T103	UMLS:C0052605
28317028	100	113	mycobacterial	T007	UMLS:C0026912
28317028	114	135	caseinolytic protease	T103	UMLS:C0052605
28317028	136	143	ClpP1P2	T103	UMLS:C0052605
28317028	149	169	degradative protease	T103	UMLS:C0030940
28317028	249	253	drug	T103	UMLS:C0013227
28317028	265	277	tuberculosis	T038	UMLS:C0041296
28317028	307	314	ClpP1P2	T103	UMLS:C0052605
28317028	315	324	inhibitor	T103	UMLS:C0014432
28317028	330	335	human	T204	UMLS:C0086418
28317028	336	356	proteasome inhibitor	T103	UMLS:C1443643
28317028	357	367	bortezomib	T103	UMLS:C1176309
28317028	444	453	bacterial	T007	UMLS:C0004611
28317028	466	476	inhibition	T038	UMLS:C1524081
28317028	480	487	ClpP1P2	T103	UMLS:C0052605
28317028	515	537	antimicrobial activity	T038	UMLS:C1149574
28317028	593	629	caseinolytic protease gene regulator	T103	UMLS:C1336776
28317028	630	634	ClgR	T103	UMLS:C1336776
28317028	658	671	clpP1P2 genes	T017	UMLS:C1335528
28317028	701	721	transcription factor	T103	UMLS:C0040648
28317028	748	756	protease	T103	UMLS:C0030940
28317028	774	782	promoter	T103	UMLS:C0086860
28317028	850	860	bortezomib	T103	UMLS:C1176309
28317028	874	897	Mycobacterium bovis BCG	T007	UMLS:C0085957
28317028	908	921	transcription	T038	UMLS:C0040649
28317028	925	932	clpP1P2	T017	UMLS:C1335528
28317028	943	947	ClgR	T103	UMLS:C1336776
28317028	960	969	promoters	T103	UMLS:C0086860
28317028	987	997	inhibition	T038	UMLS:C1524081
28317028	1001	1008	ClpP1P2	T103	UMLS:C0052605
28317028	1019	1027	cellular	T017	UMLS:C0007634
28317028	1028	1032	ClgR	T103	UMLS:C1336776
28317028	1062	1085	red fluorescent protein	T103	UMLS:C0960938
28317028	1088	1092	ClgR	T103	UMLS:C1336776
28317028	1093	1099	fusion	T058	UMLS:C1293131
28317028	1100	1108	analyses	T062	UMLS:C0936012
28317028	1122	1126	ClgR	T103	UMLS:C1336776
28317028	1152	1159	ClpP1P2	T103	UMLS:C0052605
28317028	1176	1182	ClgR's	T103	UMLS:C1336776
28317028	1183	1215	C-terminal nonapeptide APVVSLAVA	T103	UMLS:C0030956
28317028	1271	1290	protein degradation	T038	UMLS:C0597304
28317028	1294	1301	ClpP1P2	T103	UMLS:C0052605
28317028	1318	1330	accumulation	T033	UMLS:C4055506
28317028	1334	1338	ClgR	T103	UMLS:C1336776
28317028	1363	1370	bacilli	T007	UMLS:C0004587
28317028	1385	1394	mechanism	T038	UMLS:C3537153
28317028	1419	1429	inhibition	T038	UMLS:C1524081
28317028	1433	1449	ClpP1P2 protease	T103	UMLS:C0052605
28317028	1450	1458	activity	T038	UMLS:C0243102
28317028	1462	1472	bortezomib	T103	UMLS:C1176309
28317028	1500	1522	antibacterial activity	T038	UMLS:C1149575
28317028	1584	1590	deaths	T033	UMLS:C1306577
28317028	1601	1613	tuberculosis	T038	UMLS:C0041296
28317028	1625	1651	Mycobacterium tuberculosis	T007	UMLS:C0026926
28317028	1668	1686	infectious disease	T038	UMLS:C0009450
28317028	1708	1713	drugs	T103	UMLS:C0013227
28317028	1767	1774	disease	T038	UMLS:C0012634
28317028	1828	1841	mycobacterial	T007	UMLS:C0026912
28317028	1842	1850	protease	T103	UMLS:C0030940
28317028	1851	1858	ClpP1P2	T103	UMLS:C0052605
28317028	1867	1872	human	T204	UMLS:C0086418
28317028	1873	1888	anticancer drug	T103	UMLS:C0003392
28317028	1889	1899	bortezomib	T103	UMLS:C1176309
28317028	1951	1961	expression	T038	UMLS:C1171362
28317028	1970	1978	protease	T103	UMLS:C0052605
28317028	1982	1991	regulated	T038	UMLS:C2755857
28317028	1999	2007	proteins	T103	UMLS:C0033684
28317028	2015	2024	bacterium	T007	UMLS:C0004611
28317028	2028	2036	degrades	T038	UMLS:C0597304
28317028	2046	2054	protease	T103	UMLS:C0030940
28317028	2077	2085	proteins	T103	UMLS:C0033684
28317028	2099	2109	inhibition	T038	UMLS:C1524081
28317028	2113	2120	ClpP1P2	T103	UMLS:C0052605
28317028	2139	2161	antimicrobial activity	T038	UMLS:C1149574
28317028	2186	2202	ClpP1P2 protease	T103	UMLS:C0052605
28317028	2203	2212	regulates	T038	UMLS:C2755857
28317028	2221	2231	expression	T038	UMLS:C1171362
28317028	2287	2307	recognition sequence	T082	UMLS:C0002518
28317028	2314	2323	mechanism	T038	UMLS:C3537153
28317028	2332	2339	ClpP1P2	T103	UMLS:C0052605
28317028	2340	2350	inhibition	T038	UMLS:C1524081
28317028	2358	2367	bacterial	T007	UMLS:C0004611
28317028	2368	2385	growth inhibition	T038	UMLS:C2249823